Literature DB >> 32808006

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group.

Fadi Fakhouri1, Marie Scully2,3, François Provôt4,5, Miquel Blasco6, Paul Coppo5,7, Marina Noris8, Kathy Paizis9,10,11, David Kavanagh12,13, Frédéric Pène5,14,15, Sol Quezada16,17, Alexandre Hertig18, Sébastien Kissling1, Patrick O'Brien19, Yahsou Delmas5,20, Lorenzo Alberio21, Norbert Winer22,23,24,25, Agnès Veyradier5,26,27,28, Spero Cataland29, Véronique Frémeaux-Bacchi30, Chantal Loirat31, Giuseppe Remuzzi8, Vassilis Tsatsaris32.   

Abstract

Pregnancy and postpartum are high-risk periods for different forms of thrombotic microangiopathy (TMA). However, the management of pregnancy-associated TMA remains ill defined. This report, by an international multidisciplinary working group of obstetricians, nephrologists, hematologists, intensivists, neonatologists, and complement biologists, summarizes the current knowledge of these potentially severe disorders and proposes a practical clinical approach to diagnose and manage an episode of pregnancy-associated TMA. This approach takes into account the timing of TMA in pregnancy or postpartum, coexisting symptoms, first-line laboratory workup, and probability-based assessment of possible causes of pregnancy-associated TMA. Its aims are: to rule thrombotic thrombocytopenic purpura (TTP) in or out, with urgency, using ADAMTS13 activity testing; to consider alternative disorders with features of TMA (preeclampsia/eclampsia; hemolysis elevated liver enzymes low platelets syndrome; antiphospholipid syndrome); or, ultimately, to diagnose complement-mediated atypical hemolytic uremic syndrome (aHUS; a diagnosis of exclusion). Although they are rare, diagnosing TTP and aHUS associated with pregnancy, and postpartum, is paramount as both require urgent specific treatment.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32808006     DOI: 10.1182/blood.2020005221

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2021-05-05       Impact factor: 28.314

2.  How to evaluate and treat the spectrum of TMA syndromes in pregnancy.

Authors:  Marie Scully
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Pregnancy-onset thrombotic thrombocytopenic purpura with nephrotic syndrome: a case report.

Authors:  Ryunosuke Noda; Yuki Kakinuma; Kensuke Suzuki; Sanae Ide; Yuan Bae; Akito Miyauchi; Yoshitaka Ishibashi
Journal:  CEN Case Rep       Date:  2021-10-08

4.  Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases.

Authors:  Julie Boudali; Benjamin Hallak; Marie Haeck; Anne-Laure Sellier-Leclerc; Marc Ulrich; Paul Coppo; Stéphanie Tellier; François Provôt
Journal:  J Nephrol       Date:  2021-02-22       Impact factor: 3.902

5.  Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study.

Authors:  Esra Baskin; Kibriya Fidan; Bora Gulhan; Kaan Gulleroglu; Nur Canpolat; Alev Yilmaz; Gonül Parmakiz; Zeynep Birsin Özçakar; Fatih Ozaltin; Oguz Soylemezoglu
Journal:  J Nephrol       Date:  2022-01-21       Impact factor: 3.902

Review 6.  Pathological AT1R-B2R Protein Aggregation and Preeclampsia.

Authors:  Ursula Quitterer; Said AbdAlla
Journal:  Cells       Date:  2021-10-01       Impact factor: 6.600

Review 7.  Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes.

Authors:  Renaud Prével; Yahsou Delmas; Vivien Guillotin; Didier Gruson; Etienne Rivière
Journal:  J Clin Med       Date:  2022-02-01       Impact factor: 4.241

8.  Pregnancy associated TMA in 13-year-old patient successfully treated with Eculizumab: case report.

Authors:  Ellen Cody; Donna Claes; Veronica Taylor; Elif Erkan
Journal:  BMC Nephrol       Date:  2022-04-15       Impact factor: 2.585

Review 9.  Molecular Advances in Preeclampsia and HELLP Syndrome.

Authors:  Angeliki Gardikioti; Theodora-Maria Venou; Eleni Gavriilaki; Evangelia Vetsiou; Ioulia Mavrikou; Konstantinos Dinas; Angelos Daniilidis; Efthymia Vlachaki
Journal:  Int J Mol Sci       Date:  2022-03-31       Impact factor: 5.923

10.  17β-Estradiol promotes angiogenesis of bone marrow mesenchymal stem cells by upregulating the PI3K-Akt signaling pathway.

Authors:  Xiaodong Zhang; Ligang Liu; Danyang Liu; Yongtao Li; Jun He; Lei Shen
Journal:  Comput Struct Biotechnol J       Date:  2022-07-19       Impact factor: 6.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.